Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses

The main objectives are:

* To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. * To identify variables associated to higher risk of bleeding.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Manuel Monreal

Badalona, Barcelona, 08916, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients infected with COVID-19 treated with higher than recommended thromboprophylaxis doses.
Admission to hospital.

Exclusion criteria

Patients treated with ECMO (Extracorporeal membrane oxygenation).

Treatment and study plan

Primary outcomes

Bleeding events and complications

Time frame: 30 days

Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.

Sponsors and collaborators

Lead sponsor

Manuel Monreal

Other

Registry information

Official study title

Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)

Acronym: BLEEDING

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: May 8, 2020
Registry last updated: Dec 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed